
    
      This is a single arm, open label study to investigate the safety and efficacy of the use of
      OCZ103-OS in combination with standard therapy (mFOLFOX6 or FOLFIRI) as a second line
      treatment in subjects with unresectable and locally recurrent or metastatic colorectal
      cancer.
    
  